|
1
|
Lewiński A, Adamczewski Z, Zygmunt A,
Markuszewski L, Karbownik-Lewińska M and Stasiak M: Correlations
between molecular landscape and sonographic image of different
variants of papillary thyroid carcinoma. J Clin Med. 8:19162019.
View Article : Google Scholar
|
|
2
|
Ahn HS, Kim HJ and Welch HG: Korea's
thyroid-cancer ‘epidemic’-screening and overdiagnosis. N Engl J
Med. 371:1765–1767. 2014. View Article : Google Scholar : PubMed/NCBI
|
|
3
|
Kim TY, Kim WG, Kim WB and Shong YK:
Current status and future perspectives in differentiated thyroid
cancer. Endocrinol Metab (Seoul). 29:217–225. 2014. View Article : Google Scholar : PubMed/NCBI
|
|
4
|
Jung CK, Little MP, Lubin JH, Brenner AV,
Wells SAJ, Sigurdson AJ and Nikiforov YE: The increase in thyroid
cancer incidence during the last four decades is accompanied by a
high frequency of BRAF mutations and a sharp increase in RAS
mutations. J Clin Endocrinol Metab. 99:E276–E285. 2014. View Article : Google Scholar : PubMed/NCBI
|
|
5
|
Pusztaszeri M and Auger M: Update on the
cytologic features of papillary thyroid carcinoma variants. Diagn
Cytopathol. 45:714–730. 2017. View
Article : Google Scholar : PubMed/NCBI
|
|
6
|
Liang J, Cai W, Feng D, Teng H, Mao F,
Jiang Y, Hu S, Li X, Zhang Y, Liu B and Sun ZS: Genetic landscape
of papillary thyroid carcinoma in the Chinese population: Somatic
mutational profile of PTC in China. J Pathol. 244:2017.PubMed/NCBI
|
|
7
|
Larsen PR: New guidelines for patients
with thyroid nodules and differentiated thyroid cancer. Nat Clin
Pract Endocrinol Metab. 2:2972006. View Article : Google Scholar : PubMed/NCBI
|
|
8
|
Tang KT and Lee CH: BRAF mutation in
papillary thyroid carcinoma: Pathogenic role and clinical
implications. J Chin Med Assoc. 73:113–128. 2010. View Article : Google Scholar : PubMed/NCBI
|
|
9
|
Sobin LH: Histological typing of thyroid
tumours. Histopathology. 16:5131990. View Article : Google Scholar : PubMed/NCBI
|
|
10
|
McGuire S: World Cancer Report 2014.
Geneva, Switzerland: World Health Organization, International
Agency for Research on Cancer, WHO Press, 2015. Adv Nutr.
7:418–419. 2016. View Article : Google Scholar : PubMed/NCBI
|
|
11
|
Ito Y, Higashiyama T, Takamura Y, Miya A,
Kobayashi K, Matsuzuka F, Kuma K and Miyauchi A: Prognosis of
patients with benign thyroid diseases accompanied by incidental
papillary carcinoma undetectable on preoperative imaging tests.
World J Surg. 31:1672–1676. 2007. View Article : Google Scholar : PubMed/NCBI
|
|
12
|
Haugen BR, Alexander EK, Bible KC, Doherty
GM, Mandel SJ, Nikiforov UE, Pacini F, Randolph GW, Sawka AM,
Schlumberger M, et al: 2015 American Thyroid Association Management
Guidelines for Adult Patients with Thyroid Nodules and
Differentiated Thyroid Cancer: The American Thyroid Association
Guidelines Task Force on Thyroid Nodules and Differentiated Thyroid
Cancer. Thyroid. 26:1–133. 2016. View Article : Google Scholar : PubMed/NCBI
|
|
13
|
Chen JF, Cao J, Qiu FQ and Huang PT: The
efficacy and the safety of ultrasound-guided ablation therapy for
treating papillary thyroid microcarcinoma. J Cancer. 10:5272–5282.
2019. View Article : Google Scholar : PubMed/NCBI
|
|
14
|
Zheng X, Peng C, Gao M, Zhi J, Hou X, Zhao
J, Wei X, Chi J, Li D and Qian BK: Risk factors for cervical lymph
node metastasis in papillary thyroid microcarcinoma: A study of
1,587 patients. Cancer Biol Med. 16:121–130. 2019. View Article : Google Scholar : PubMed/NCBI
|
|
15
|
Jeon MJ, Kim WG, Chung K, Baek JH, Kim WB
and Shong YK: Active surveillance of papillary thyroid
microcarcinoma: Where do we stand? Eur Thyroid J. 8:298–306. 2019.
View Article : Google Scholar : PubMed/NCBI
|
|
16
|
Robb R, Yang L, Shen C, Wolfe AR, Webb A,
Zhang X, Vedaie M, Saji M, Jhiang S, Ringel MD, Williams TM, et al:
Inhibiting BRAF oncogene-mediated radioresistance effectively
radiosensitizes BRAFV600E-mutant thyroid cancer cells by
constraining DNA double-strand break repair. Clin Cancer Res.
25:4749–4760. 2019. View Article : Google Scholar : PubMed/NCBI
|
|
17
|
Qiu T, Lu H, Guo L, Huang W, Ling Y, Shan
L, Li W, Ying J and Lv N: Detection of BRAF mutation in Chinese
tumor patients using a highly sensitive antibody
immunohistochemistry assay. Sci Rep. 5:92112015. View Article : Google Scholar : PubMed/NCBI
|
|
18
|
Landa I, Pozdeyev N, Korch C, Marlow LA,
Smallridge RC, Copland JA, Henderson YC, Lai SY, Clayman GL, Onoda
N, et al: Comprehensive genetic characterization of human thyroid
cancer cell lines: A validated panel for preclinical studies. Clin
Cancer Res. 25:3141–3151. 2019. View Article : Google Scholar : PubMed/NCBI
|
|
19
|
Kim ES, Lee Y, Seo H, Son GS, Kwon SY, Kim
YS, Seo J, Kim NH, Suh S, Ryoo I and You SH: Clinical features of
recently diagnosed papillary thyroid carcinoma in elderly patients
aged 65 and older based on 10 years of sonographic experience at a
single institution in Korea. Ultrasonography. 36:355–362. 2017.
View Article : Google Scholar : PubMed/NCBI
|
|
20
|
Lutz BS, Leguisamo NM, Cabral NK, Gloria
HC, Reiter KC, Agnes G, Zanella V, Meyer ELS and Saffi J: Imbalance
in DNA repair machinery is associated with BRAF(V600E) mutation and
tumor aggressiveness in papillary thyroid carcinoma. Mol Cell
Endocrinol. 472:140–148. 2018. View Article : Google Scholar : PubMed/NCBI
|
|
21
|
Chen Y, Sadow PM, Suh H, Lee KE, Choi JY,
Suh YJ, Wang TS and Lubitz CC: BRAF(V600E) is correlated with
recurrence of papillary thyroid microcarcinoma: A systematic
review, multi-institutional primary data analysis, and
meta-analysis. Thyroid. 26:248–255. 2016. View Article : Google Scholar : PubMed/NCBI
|
|
22
|
Li F, Chen G, Sheng C, Gusdon AM, Huang Y,
Lv Z, Xu H, Xing M and Qu S: BRAFV600E mutation in papillary
thyroid microcarcinoma: A meta-analysis. Endocr-Relat Cancer.
22:159–168. 2015. View Article : Google Scholar : PubMed/NCBI
|
|
23
|
Lee YH, Lee YM, Sung TY, Yoon JH, Song DE,
Kim TY, Baek JH, Ryu JS, Chung KW and Hong SJ: Is male gender a
prognostic factor for papillary thyroid microcarcinoma? Ann Surg
Oncol. 24:1958–1964. 2017. View Article : Google Scholar : PubMed/NCBI
|
|
24
|
Kim TY, Kim WB, Song JY, Rhee YS, Gong G,
Cho YM, Kim SY, Kim SC, Hong SJ and Shong YK: The BRAF mutation is
not associated with poor prognostic factors in Korean patients with
conventional papillary thyroid microcarcinoma. Clin Endocrinol
(Oxf). 63:588–593. 2005. View Article : Google Scholar : PubMed/NCBI
|
|
25
|
Kwak JY, Kim EK, Chung WY, Moon HJ, Kim MJ
and Choi JR: Association of BRAFV600E mutation with poor clinical
prognostic factors and US features in Korean patients with
papillary thyroid microcarcinoma. Radiologe. 253:854–860. 2009.
|
|
26
|
Chen B, Zhang Z, Wang K, Shang M, Zhao S,
Ding W, Du R, Yu Z and Xu X: Association of BRAFV600E mutation with
ultrasonographic features and clinicopathologic characteristics of
papillary thyroid microcarcinoma: A retrospective study of 116
cases. Clin Hemorheol Micro. 73:545–552. 2019.
|
|
27
|
Choi SY, Park H, Kang MK, Lee DK, Lee KD,
Lee HS, Kim SW, Lee EN and Hong JC: The relationship between the
BRAF(V600E) mutation in papillary thyroid microcarcinoma and
clinicopathologic factors. World J Surg Oncol. 11:2912013.
View Article : Google Scholar : PubMed/NCBI
|
|
28
|
Rothenberg SM, Mcfadden DG, Palmer EL,
Daniels GH and Wirth LJ: Redifferentiation of iodine-refractory
BRAF V600E-mutant metastatic papillary thyroid cancer with
dabrafenib. Clin Cancer Res. 21:1028–1035. 2015. View Article : Google Scholar : PubMed/NCBI
|
|
29
|
Mingzhao X: Molecular pathogenesis and
mechanisms of thyroid cancer. Nat Rev Cancer. 13:184–199. 2013.
View Article : Google Scholar : PubMed/NCBI
|
|
30
|
Zheng X, Wei S, Han Y, Li Y, Yu Y, Yun X,
Ren X and Gao M: Papillary microcarcinoma of the thyroid: Clinical
characteristics and BRAF(V600E) mutational status of 977 cases. Ann
Surg Oncol. 20:2266–2273. 2013. View Article : Google Scholar : PubMed/NCBI
|
|
31
|
Koelsch B, Theurer S, Staniszewska M,
Heupel J, Koch A, Mergener S, Walk F, Fischer C, Kutritz A, Schmid
KW and Kindler-Röhrborn A: An animal model further uncovers the
role of mutant BrafV600E during papillary thyroid cancer
development. Am J Pathol. 190:702–710. 2020. View Article : Google Scholar : PubMed/NCBI
|
|
32
|
Lang HH, Chai YJ, Cowling BJ, Min HS, Lee
KE and Youn YK: Is BRAFV600E mutation a marker for central nodal
metastasis in small papillary thyroid carcinoma? Endocr Relat
Cancer. 21:285–295. 2014. View Article : Google Scholar : PubMed/NCBI
|
|
33
|
Roh JL, Kim J and Park CI: Central
cervical nodal metastasis from papillary thyroid microcarcinoma:
Pattern and factors predictive of nodal metastasis. Ann Surg Oncol.
15:2482–2486. 2008. View Article : Google Scholar : PubMed/NCBI
|
|
34
|
Sun Y, Hongjun L, Shaoqiang Z, Yanxia B
and Bingyin S: Gender-specific risk of central compartment lymph
node metastasis in papillary thyroid carcinoma. Int J Endocrinol.
2018:67103262018. View Article : Google Scholar : PubMed/NCBI
|
|
35
|
Kilfoy BA, Devesa SS, Ward MH, Zhang Y,
Rosenberg PS, Holford TR and Anderson WF: Gender is an age-specific
effect modifier for papillary cancers of the thyroid gland. Cancer
Epidemiol Biomarkers Prev. 18:1092–1100. 2009. View Article : Google Scholar : PubMed/NCBI
|
|
36
|
Rahbari R, Zhang L and Kebebew E: Thyroid
cancer gender disparity. Future Oncol. 6:1771–1779. 2010.
View Article : Google Scholar : PubMed/NCBI
|
|
37
|
Li M, Zhu X, Lv J, Lu K, Shen M, Xu Z and
Wu Z: Risk factors for predicting central lymph node metastasis in
papillary thyroid microcarcinoma (CN0): A study of 273 resections.
Eur Rev Med Pharmaco. 21:3801–3807. 2017.
|
